NRXPWHIGH SIGNALFINANCIAL10-K

NRXPW shows dramatic balance sheet improvement with cash increasing 440% to $7.8M and total assets growing 255%, but operating losses deepened by 33% amid continued R&D spending reductions.

The massive cash infusion and improved stockholders equity position suggests significant financing activity that has temporarily strengthened the company's financial position. However, the worsening operating cash flow burn rate of $14.1M annually against only $7.8M in cash indicates potential liquidity concerns within 6-9 months without additional funding.

Comparing 2026-03-23 vs 2025-03-14View on EDGAR →
FINANCIAL ANALYSIS

The company experienced a dramatic financial transformation with cash and total assets surging 440% and 255% respectively, while stockholders equity improved significantly from -$23.2M to -$15.9M, suggesting major equity financing. However, operational performance deteriorated with R&D expenses cut 39% to $3.8M, net losses widening to $28.6M, and operating cash flow burn increasing 33% to $14.1M annually. Despite the balance sheet improvements, the accelerating cash burn against current cash levels signals potential near-term funding needs for this clinical-stage biotech company.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
+566.7%
$18K→$120K

Interest expense surged 566.7% — significant debt increase or rising rates materially impacting earnings.

Cash & Equivalents
Balance Sheet
+440.3%
$1.4M→$7.8M

Cash position surged 440.3% — strong cash generation or capital raise providing significant financial cushion.

Total Assets
Balance Sheet
+254.9%
$3.7M→$13.0M

Asset base grew 254.9% — expansion through organic growth, acquisitions, or capital deployment.

Current Assets
Balance Sheet
+169.3%
$3.3M→$8.9M

Current assets grew 169.3% — improving short-term liquidity or inventory/receivables build.

R&D Expense
P&L
-39.1%
$6.2M→$3.8M

R&D spending cut 39.1% — could signal cost discipline or concerning reduction in innovation investment.

Operating Cash Flow
Cash Flow
-32.7%
-$10.6M→-$14.1M

Operating cash flow fell 32.7% — earnings quality concerns; investigate working capital changes and non-cash items.

Stockholders Equity
Balance Sheet
+31.4%
-$23.2M→-$15.9M

Equity base grew 31.4% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Current Liabilities
Balance Sheet
+30.7%
$21.9M→$28.6M

Current liabilities surged 30.7% — significant near-term obligations; verify ability to meet short-term debt.

Net Income
P&L
-13.9%
-$25.1M→-$28.6M

Net income declined 13.9% — review whether driven by operations, interest costs, or non-recurring items.

Total Debt
Balance Sheet
-13%
$10.5M→$9.2M

Debt reduced 13% — deleveraging strengthens balance sheet and reduces financial risk.

LANGUAGE CHANGES
NEW — 2026-03-23
PRIOR — 2025-03-14
ADDED
false --12-31 FY 2025 true true true The Audit Committee of the Board of Directors oversees NRx s cybersecurity risk exposures and the steps taken by management to monitor and mitigate cybersecurity risks.
The cybersecurity stakeholders, including member(s) of management assigned with cybersecurity oversight responsibility and/or third-party consultants providing cyber risk services, brief the Audit Committee on cyber vulnerabilities identified through the risk management process, the effectiveness of NRx s cyber risk management program, and the emerging threat landscape and new cyber risks on at least an annual basis.
This includes updates on NRx's processes to prevent, detect, and mitigate cybersecurity incidents.
The Audit Committee of the Board of Directors oversees NRx s cybersecurity risk exposures and the steps taken by management to monitor and mitigate cybersecurity risks.
The cybersecurity stakeholders, including member(s) of management assigned with cybersecurity oversight responsibility and/or third-party consultants providing cyber risk services, brief the Audit Committee on cyber vulnerabilities identified through the risk management process, the effectiveness of NRx s cyber risk management program, and the emerging threat landscape and new cyber risks on at least an annual basis.
+7 more — sign up free →
REMOVED
As of March 14, 2025, the registrant had 16,915,647 shares of common stock outstanding.
(Nasdaq: NRXP) ( NRX or the Company ) is a clinical-stage bio-pharmaceutical company which develops and will distribute, through its wholly-owned operating subsidiary, NeuroRx, Inc.
( NeuroRx ), novel therapeutics for the treatment of central nervous system disorders including suicidal depression, chronic pain, and post-traumatic stress disorder ( PTSD ) and now schizophrenia.
All of our current drug development activities are focused drugs that modulate on the N-methyl-D-aspartate ( NMDA ) receptor in the brain and nervous system, a neurochemical pathway that has been disclosed in detail in our annual filings.
The Company has two lead drug candidates that are expected to be submitted by year end for Food and Drug Administration ("FDA") approval with anticipated FDA decision dates under the Prescription Drug User Fee Act ( PDUFA ) by the end of June 2025: NRX-101, an oral fixed dose combination of D-cycloserine and lurasidone and NRX-100, a preservative-free formulation of ketamine for intravenous infusion.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →